OptiBiotix Health (LSE:OPTI) reported a 21.9% increase in revenue to £679,000 for the first half of 2026, alongside a 25.4% rise in gross profit and reductions in operating expenditure.
The life sciences company said revenue growth in Asia and other Rest of World markets offset lower sales in the United States and India.
Gross margins improved during the period, while reductions in selling, research and development, and other operating costs contributed to lower expenditure.
OptiBiotix ended the first half with positive net assets, cash of nearly £1 million and no debt.
The company reported an expanding pipeline of potential customers as it continued commercialising its microbiome-based products across international markets.
During the period, OptiBiotix fulfilled orders for its SlimBiome weight management ingredient in Taiwan and expanded lower-cost production capacity in India.
The group also introduced artificial intelligence tools to improve the performance of its marketing activities on Amazon.
Following the period-end, OptiBiotix signed trademark licensing agreements with a large US corporation and a direct-selling group to support the launch of SlimBiome products in the United States and India.
The company also introduced products through FORMI, a new brand developed by health and wellness retailer Holland & Barrett.
Development work continued on SweetBiotix, OptiBiotix’s range of sweet fibres. The company distributed samples to international food and beverage businesses for evaluation as it progresses the products towards commercialisation.
OptiBiotix’s existing product portfolio includes SlimBiome and WellBiome, which target weight management and digestive health through microbiome-based formulations.
Its development pipeline also includes SweetBiotix and specialised prebiotics designed to influence the gut microbiome.
The company holds investments in ProBiotix Health plc and SkinBioTherapeutics plc, providing additional exposure to probiotic and skin health products.
OptiBiotix continues to develop its manufacturing, licensing and distribution arrangements across the UK, Europe, Asia and other international markets as it seeks to expand sales of its existing products and commercialise its development pipeline.
Leave a Reply